Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-22T06:49:35.994Z Has data issue: false hasContentIssue false
  • English
  • Français

Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium

Published online by Cambridge University Press:  21 February 2012

Sharon E. Johnatty ,
Jonathan Beesley ,
Xiaoqing Chen ,
Amanda B. Spurdle ,
Anna DeFazio ,
Penelope M. Webb ,
Ellen L. Goode ,
David N. Rider ,
Robert A. Vierkant  and
Stephanie Anderson
...Show all authors
Sharon E. Johnatty
Affiliation:
Queensland Institute of Medical Research, Brisbane, Queensland, Australia.
Jonathan Beesley
Affiliation:
Queensland Institute of Medical Research, Brisbane, Queensland, Australia.
Xiaoqing Chen
Affiliation:
Queensland Institute of Medical Research, Brisbane, Queensland, Australia.
Amanda B. Spurdle
Affiliation:
Queensland Institute of Medical Research, Brisbane, Queensland, Australia.
Anna DeFazio
Affiliation:
Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia.
Penelope M. Webb
Affiliation:
Queensland Institute of Medical Research, Brisbane, Queensland, Australia.
Ellen L. Goode
Affiliation:
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
David N. Rider
Affiliation:
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
Robert A. Vierkant
Affiliation:
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
Stephanie Anderson
Affiliation:
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
Anna H. Wu
Affiliation:
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America.
Malcolm Pike
Affiliation:
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America.
David Van Den Berg
Affiliation:
Department of Urology, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America.
Kirsten Moysich
Affiliation:
Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Roberta Ness
Affiliation:
The University of Texas School of Public Health, Houston, Texas, United States of America.
Jennifer Doherty
Affiliation:
Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA,, United States of America.
Mary-Anne Rossing
Affiliation:
Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA,, United States of America.
Celeste Leigh Pearce
Affiliation:
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America.
Georgia Chenevix-Trench*
Affiliation:
Queensland Institute of Medical Research, Brisbane, Queensland, Australia. [email protected]
*
*Address for correspondence: G. Chenevix-Trench, Cancer and Cell Biology, Queensland Institute of Medical Research, c/o Royal Brisbane Hospital Post Office, Herston, QLD 4029, Australia.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in tumor progression, and is one of several growth factors with a central role in ovarian carcinogenesis. We hypothesized that common single nucleotide polymorphisms (SNPs) in the FGF2 gene may alter angiogenic potential and thereby susceptibility to ovarian cancer. We analyzed 25 FGF2 tgSNPs using five independent study populations from the United States and Australia. Analysis was restricted to non-Hispanic White women with serous ovarian carcinoma (1269 cases and 2829 controls). There were no statistically significant associations between any FGF2 SNPs and ovarian cancer risk. There were two nominally statistically significant associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; p < .05) and serous ovarian cancer risk in the combined dataset, but rare homozygous estimates did not achieve statistical significance, nor were they consistent with the log additive model of inheritance. Overall genetic variation in FGF2 does not appear to play a role in susceptibility to ovarian cancer.

Keywords

ovarian cancerserousbasic fibroblast growth factorpolymorphismsFGF2
Type
Articles
Information
Twin Research and Human Genetics , Volume 12 , Issue 3 , 01 June 2009 , pp. 269 - 275
Copyright
Copyright © Cambridge University Press 2009